Faeth Therapeutics, Inc. Financing Cash Flow
Faeth Therapeutics, Inc. (FTH) reported Financing Cash Flow of $184.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.68M.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $185.83M.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$111.00K.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$152.00K.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$645.00K.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$787.00K.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$11.17M.
- Faeth Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$287.00K, a 100.18% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $184.14M 10-Q · filed 2026-08-04 | $184.03M derived: sum of 3 quarters · filed 2026-08-04 | $183.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $185.83M 10-Q · filed 2026-05-15 | $185.72M derived: sum of 2 quarters · filed 2026-05-15 | $185.56M derived: sum of 3 quarters · filed 2026-05-15 | $185.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$263.00K derived: sum of 2 quarters · filed 2026-03-30 | -$431.00K derived: sum of 3 quarters · filed 2026-08-04 | -$645.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$152.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$320.00K derived: sum of 2 quarters · filed 2026-08-04 | -$534.00K 10-Q · filed 2025-11-14 | -$728.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$382.00K 10-Q · filed 2026-08-04 | -$576.00K derived: sum of 3 quarters · filed 2026-08-04 | -$780.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$214.00K 10-Q · filed 2026-05-15 | -$408.00K derived: sum of 2 quarters · filed 2026-05-15 | -$612.00K derived: sum of 3 quarters · filed 2026-05-15 | -$792.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$398.00K derived: sum of 2 quarters · filed 2026-03-30 | -$578.00K derived: sum of 3 quarters · filed 2026-03-30 | -$787.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$384.00K derived: sum of 2 quarters · filed 2025-11-14 | -$593.00K 10-Q · filed 2025-11-14 | -$1.02M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$389.00K 10-Q · filed 2025-08-05 | -$820.00K derived: sum of 3 quarters · filed 2025-08-05 | -$3.35M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$209.00K 10-Q · filed 2025-05-06 | -$640.00K derived: sum of 2 quarters · filed 2025-05-06 | -$3.17M derived: sum of 3 quarters · filed 2025-05-06 | -$11.12M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$2.96M derived: sum of 2 quarters · filed 2025-03-28 | -$10.91M derived: sum of 3 quarters · filed 2025-03-28 | -$11.17M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$10.48M derived: sum of 2 quarters · filed 2024-11-14 | -$10.74M 10-Q · filed 2024-11-14 | -$10.87M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$7.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$8.21M 10-Q · filed 2024-08-06 | -$8.33M derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$262.00K 10-Q · filed 2024-05-09 | -$386.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$287.00K 10-K · filed 2024-02-29 | ||
| 2022-09-30 | -$163.00K 10-Q · filed 2023-11-07 | |||
| 2022-03-31 | $119.00K 10-Q · filed 2023-05-09 | $1.00K derived: sum of 2 quarters · filed 2023-05-09 | -$6.00K derived: sum of 3 quarters · filed 2023-05-09 | -$17.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$125.00K derived: sum of 2 quarters · filed 2023-03-29 | -$136.00K derived: sum of 3 quarters · filed 2023-03-29 | $163.94M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$18.00K derived: sum of 2 quarters · filed 2022-11-08 | $164.06M 10-Q · filed 2022-11-08 | $179.92M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $164.06M 10-Q · filed 2022-08-09 | $179.92M derived: sum of 3 quarters · filed 2022-08-09 | $188.41M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $164.08M 10-Q · filed 2022-05-10 | $179.94M derived: sum of 2 quarters · filed 2022-05-10 | $188.42M derived: sum of 3 quarters · filed 2022-05-10 | $188.97M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $24.34M derived: sum of 2 quarters · filed 2022-03-15 | $24.90M derived: sum of 3 quarters · filed 2022-03-15 | $35.45M 10-K · filed 2022-03-15 |
| 2020-09-30 | $8.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.04M derived: sum of 2 quarters · filed 2021-11-10 | $19.59M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $556.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $11.11M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $10.56M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |